Evidence map›Paper›PMID 40496139›Full record

ReviewFrontiers in cell and developmental biology2025

Emerging roles for E3 ubiquitin ligases in neural development and disease.

Maya Hale, Greg J Bashaw

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. The Roles of E3 Ubiquitin Ligases in Cerebral Ischemia-Reperfusion Injury.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Maya HaleDepartment of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Greg J BashawDepartment of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Funding

Molecular mechanisms of axon guidance receptor regulation and signalingR35NS097340 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI BASHAW, GREG J. · 2017 to 2024
$5.8M
Regulation of axon guidance receptor trafficking in the developing mammalian central nervous systemR01HD105946 · NICHD · UNIVERSITY OF PENNSYLVANIA · PI BASHAW, GREG J. · 2021 to 2025
$2.3M
NICHD NIH HHS R01 HD105946NINDS NIH HHS R35 NS097340
6 · The paper itself

Abstract

Neurodevelopment is an intricate process with highly regulated, overlapping stages including neuronal differentiation and axon guidance. Aberrations during these and other stages are tied to the etiology of neurodevelopmental disorders like Autism Spectrum Disorder, Angelman Syndrome, and X-linked Intellectual Disability. Ubiquitination is a dynamic and highly reversible post-translational modification conferred by E3 ubiquitin ligases. Recent discoveries have advanced the understanding of how substrate ubiquitination can guide protein localization, drive protein degradation, and alter protein post translational modifications. In this review, we highlight members of the RING and HECT E3 ligase families to discuss their novel roles in the molecular mechanisms regulating neurodevelopment. These findings are both instrumental for informing the future directions of neurodevelopmental research, and in expanding knowledge of intracellular mechanisms of protein trafficking. In addition, a deeper understanding of the molecular mechanisms of E3 ligase function in development promises to offer new insights into the pathogenesis of neurodevelopmental disorders.

Indexed as

axon guidancecommissurelessE3 ubiquitin ligaseNdfipneural developmental disordersneural differentiationslit

Identifiers

PMID40496139
PMCPMC12149146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.